Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7243 results

Sort By:

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Study ID: NCT05789303
Start Date: 2023-05-30
End Date: 2028-07-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

83

Intervention / Treatment

Mafodotin Belantamab

Carfilzomib

Pomalidomide

Dexamethasone

Sponsor

University of Chicago

Source: clinicaltrials.gov

Share:
Add to list

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Study ID: NCT05394103
Start Date: 2022-08-30
End Date: 2026-08-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

130

Intervention / Treatment

Q901

KEYTRUDA® (pembrolizumab)

Sponsor

Qurient Co., Ltd.

Source: clinicaltrials.gov

Share:
Add to list

Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

Study ID: NCT06796543
Start Date: 2025-03-25
End Date: 2030-03
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

70

Intervention / Treatment

Consolidative radiation therapy (cRT)

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Source: clinicaltrials.gov

Share:
Add to list

Tislelizumab in People With Colorectal Cancer

Study ID: NCT06529523
Start Date: 2024-07-26
End Date: 2028-07
Study Type

Interventional

Study Phase

Phase2

No. of Participants

40

Intervention / Treatment

Tiskelizumab

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer

Study ID: NCT05477823
Start Date: 2023-03-08
End Date: 2027-08
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

30

Intervention / Treatment

External beam radiation therapy

Prostate brachytherapy boost

Androgen deprivation therapy

Positron emission tomography (PET)/magnetic resonance imaging (MRI)

Sponsor

University of Wisconsin, Madison

Source: clinicaltrials.gov

Share:
Add to list

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Study ID: NCT04570423
Start Date: 2021-05-20
End Date: 2027-10
Study Type

Interventional

Study Phase

Phase2

No. of Participants

40

Intervention / Treatment

Pilgrimage

Chemotherapy

Sponsor

Spectrum Pharmaceuticals, Inc

Source: clinicaltrials.gov

Share:
Add to list

The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer

Study ID: NCT05502523
Start Date: 2022-08-31
End Date: 2029-01-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

100

Intervention / Treatment

Pulmonary Artery-First Surgical Technique

Biospecimen Collection

Sponsor

Thomas Jefferson University

Source: clinicaltrials.gov

Share:
Add to list

UNC Childhood, Adolescent, and Young Adult Cancer Cohort

Study ID: NCT05096923
Start Date: 2021-12-17
End Date: 2031-12-31
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

500

Intervention / Treatment
Sponsor

UNC Lineberger Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer

Study ID: NCT06073223
Start Date: 2023-09-18
End Date: 2025-10
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

70

Intervention / Treatment

Usual Care

CQUPLE

Sponsor

University of Michigan Rogel Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

Study ID: NCT06788938
Start Date: 2025-03-21
End Date: 2029-04-24
Study Type

Interventional

Study Phase

Phase2

No. of Participants

29

Intervention / Treatment

Tarlatamab treatment

Sponsor

Jonsson Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list